Phase 2a trial opens testing two dosing regimens of 177Lu-TLX250 in advanced clear cell RCC
Trial opening · ClinicalTrials.gov · 2026-10-13. Number 1 in the UrologyWatch Top 5 for October 17, 2026.
A multicenter phase 2a study (planned enrollment 40) will evaluate two dosing regimens of the CAIX-targeted radioligand therapy 177Lu-TLX250 in relapsed or recurrent clear cell renal cell carcinoma, aiming to determine a recommended phase 3 dose.
Why it matters: CAIX-targeted radioligand therapy represents an emerging treatment approach for clear cell RCC, a tumor type with few radiopharmaceutical options to date.
Source: ClinicalTrials.gov
Loading today's edition…